"And so I'm not saying Reddit solves all these issues, but it does give us a different population that's pretty large to see what's happening." Sehgal emphasized that the study does not claim the symptoms are caused by GLP1 drugs
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH) developed by Novo Nordisk, displaying high GH-releasing potency and efficacy both in vitro and in vivo
However, as weight loss progresses, individuals may experience a decrease in the intensity or frequency of their workouts
